Biotech Values

[DewDiligence]

PFE-BHVN correction—#msg-168806558 mistakenly says that shareholders of “both companies” will receive 0.5 shares of a newly formed (as yet unnamed) company that will retain BHVN’s non-migraine, early-stage pipeline. In fact, only BHVN shareholders will receive shares of this new company. PFE itself (a 3% owner of BHVN prior to the buyout deal) will get shares of this newly formed company, but PFE’s shareholders will not.